TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial - The Lancet Oncology
Roche - Avastin (bevacizumab)
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
Italy free to reimburse off-label Avastin, rules EU court -
Bevacizumab-awwb becomes first biosimilar approved for cancer treatment | MDedge Hematology and Oncology
More Medicare Musings: Why Lucentis is Worth the Price Tag - Eyedolatry
NHS wins legal fight against pharma firms over sight-loss drug | NHS | The Guardian
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open- label, phase 3 trial - The Lancet
PLOS ONE: A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
Genentech warns of fake Avastin
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook - Cancer Treatment Reviews
File:Bevacizumab label 01.jpg - wikidoc
Avastin Injections Are Said to Cause Blindness - The New York Times
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study - The Lancet Oncology
New Bevacizumab biosimilar launched by Clonmel
Immunotherapy Regimen Approved for Hepatocellular Carcinoma - MPR
NHS wins legal fight with pharma over off-label Avastin - PMLiVE
PLOS ONE: A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
Avastin - FDA prescribing information, side effects and uses
PDF) Bevacizumab: Off-label use in ophthalmology
Five cancer drugs back on NHS list after deals with drug companies | The BMJ
Avastin's breast cancer use to continue in Europe | Pharmafile
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial - European Journal of Cancer
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
avastin - Diabetic Retinopathy
